GIM-407
/ Georgiamune
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 15, 2026
GIM-407 Phase 2a Pilot Study in Adults with Coeliac Disease
(ANZCTR)
- P2 | N=20 | Not yet recruiting | Sponsor: Georgiamune Australia Pty Ltd
New P2 trial • Celiac Disease • Immunology
July 10, 2025
The Purpose of the Study is to Evaluate the Safety, Tolerability and Pharmacokinetics of Single-ascending and Multiple-ascending Doses of GIM-407
(clinicaltrials.gov)
- P1 | N=48 | Completed | Sponsor: Georgiamune Inc | Recruiting ➔ Completed | N=80 ➔ 48
Enrollment change • Trial completion
September 20, 2024
The Purpose of the Study is to Evaluate the Safety, Tolerability and Pharmacokinetics of Single-ascending and Multiple-ascending Doses of GIM-407
(clinicaltrials.gov)
- P1 | N=64 | Recruiting | Sponsor: Georgiamune Inc | Not yet recruiting ➔ Recruiting
Enrollment open
August 02, 2024
The Purpose of the Study is to Evaluate the Safety, Tolerability and Pharmacokinetics of Single-ascending and Multiple-ascending Doses of GIM-407
(clinicaltrials.gov)
- P1 | N=64 | Not yet recruiting | Sponsor: Georgiamune Inc
New P1 trial
1 to 4
Of
4
Go to page
1